Cargando…

Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*

SUMMARY: BACKGROUND: Plaque psoriasis has a relatively high prevalence in adolescence, resulting in a significant impact on quality of life, including social interactions. OBJECTIVES: The primary objective was to assess the safety of once-daily application of fixed-combination calcipotriol plus beta...

Descripción completa

Detalles Bibliográficos
Autores principales: Gooderham, M, Debarre, J-M, Keddy-Grant, J, Xu, Z, Kurvits, M, Goodfield, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298245/
https://www.ncbi.nlm.nih.gov/pubmed/24980277
http://dx.doi.org/10.1111/bjd.13235
_version_ 1782353241954058240
author Gooderham, M
Debarre, J-M
Keddy-Grant, J
Xu, Z
Kurvits, M
Goodfield, M
author_facet Gooderham, M
Debarre, J-M
Keddy-Grant, J
Xu, Z
Kurvits, M
Goodfield, M
author_sort Gooderham, M
collection PubMed
description SUMMARY: BACKGROUND: Plaque psoriasis has a relatively high prevalence in adolescence, resulting in a significant impact on quality of life, including social interactions. OBJECTIVES: The primary objective was to assess the safety of once-daily application of fixed-combination calcipotriol plus betamethasone dipropionate gel in adolescent scalp psoriasis. Assessment of efficacy was a secondary objective. METHODS: This phase II, multicentre, single-arm, open-label, 8-week trial included patients aged 12–17 years with moderate-to-very severe scalp psoriasis according to Investigator's Global Assessment (IGA) (≥ 10% of the scalp area affected). RESULTS: Seventy-eight patients received treatment. Twenty-seven patients (35%) reported a total of 64 adverse events (AEs); most were mild (33/64) or moderate (22/64) in severity and there were no serious AEs. No cases of hypercalcaemia were reported, and the mean changes from baseline to end of treatment in albumin-corrected serum calcium (0·00 mmol L(−1)), 24-h urinary calcium excretion (−0·03 mmol per 24 h) and urinary calcium-to-creatinine ratio (−0·12 mmol g(−1)) were not considered clinically relevant. At the end of treatment 66 patients (85%) were clear or almost clear according to IGA. There was an 80% improvement in mean Total Sign Score from baseline to end of treatment. In total, at the end of treatment, 87% of patients rated their scalp psoriasis as clear or very mild, and 75 (96%) had no or mild pruritus compared with 14 (18%) at baseline. CONCLUSIONS: Once-daily calcipotriol plus betamethasone dipropionate gel is well tolerated and efficacious for scalp psoriasis in adolescents. WHAT'S ALREADY KNOWN ABOUT THIS TOPIC? Calcipotriol plus betamethasone dipropionate gel is a well-tolerated and efficacious treatment for scalp and body psoriasis in adults. . Psoriasis can present during childhood or adolescence and may negatively impact quality of life. . WHAT DOES THIS STUDY ADD? Calcipotriol plus betamethasone dipropionate gel is well tolerated and shows efficacy for treatment of scalp psoriasis in an adolescent population. .
format Online
Article
Text
id pubmed-4298245
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42982452015-01-27 Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age* Gooderham, M Debarre, J-M Keddy-Grant, J Xu, Z Kurvits, M Goodfield, M Br J Dermatol Original Articles SUMMARY: BACKGROUND: Plaque psoriasis has a relatively high prevalence in adolescence, resulting in a significant impact on quality of life, including social interactions. OBJECTIVES: The primary objective was to assess the safety of once-daily application of fixed-combination calcipotriol plus betamethasone dipropionate gel in adolescent scalp psoriasis. Assessment of efficacy was a secondary objective. METHODS: This phase II, multicentre, single-arm, open-label, 8-week trial included patients aged 12–17 years with moderate-to-very severe scalp psoriasis according to Investigator's Global Assessment (IGA) (≥ 10% of the scalp area affected). RESULTS: Seventy-eight patients received treatment. Twenty-seven patients (35%) reported a total of 64 adverse events (AEs); most were mild (33/64) or moderate (22/64) in severity and there were no serious AEs. No cases of hypercalcaemia were reported, and the mean changes from baseline to end of treatment in albumin-corrected serum calcium (0·00 mmol L(−1)), 24-h urinary calcium excretion (−0·03 mmol per 24 h) and urinary calcium-to-creatinine ratio (−0·12 mmol g(−1)) were not considered clinically relevant. At the end of treatment 66 patients (85%) were clear or almost clear according to IGA. There was an 80% improvement in mean Total Sign Score from baseline to end of treatment. In total, at the end of treatment, 87% of patients rated their scalp psoriasis as clear or very mild, and 75 (96%) had no or mild pruritus compared with 14 (18%) at baseline. CONCLUSIONS: Once-daily calcipotriol plus betamethasone dipropionate gel is well tolerated and efficacious for scalp psoriasis in adolescents. WHAT'S ALREADY KNOWN ABOUT THIS TOPIC? Calcipotriol plus betamethasone dipropionate gel is a well-tolerated and efficacious treatment for scalp and body psoriasis in adults. . Psoriasis can present during childhood or adolescence and may negatively impact quality of life. . WHAT DOES THIS STUDY ADD? Calcipotriol plus betamethasone dipropionate gel is well tolerated and shows efficacy for treatment of scalp psoriasis in an adolescent population. . BlackWell Publishing Ltd 2014-12 2014-10-22 /pmc/articles/PMC4298245/ /pubmed/24980277 http://dx.doi.org/10.1111/bjd.13235 Text en © 2014 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Gooderham, M
Debarre, J-M
Keddy-Grant, J
Xu, Z
Kurvits, M
Goodfield, M
Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
title Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
title_full Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
title_fullStr Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
title_full_unstemmed Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
title_short Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
title_sort safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298245/
https://www.ncbi.nlm.nih.gov/pubmed/24980277
http://dx.doi.org/10.1111/bjd.13235
work_keys_str_mv AT gooderhamm safetyandefficacyofcalcipotriolplusbetamethasonedipropionategelinthetreatmentofscalppsoriasisinadolescents1217yearsofage
AT debarrejm safetyandefficacyofcalcipotriolplusbetamethasonedipropionategelinthetreatmentofscalppsoriasisinadolescents1217yearsofage
AT keddygrantj safetyandefficacyofcalcipotriolplusbetamethasonedipropionategelinthetreatmentofscalppsoriasisinadolescents1217yearsofage
AT xuz safetyandefficacyofcalcipotriolplusbetamethasonedipropionategelinthetreatmentofscalppsoriasisinadolescents1217yearsofage
AT kurvitsm safetyandefficacyofcalcipotriolplusbetamethasonedipropionategelinthetreatmentofscalppsoriasisinadolescents1217yearsofage
AT goodfieldm safetyandefficacyofcalcipotriolplusbetamethasonedipropionategelinthetreatmentofscalppsoriasisinadolescents1217yearsofage